Collins Helen Louise sold 3,900 shares of Enliven Therapeutics, Inc. at $58.37 for −$228k on Aug 17, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
CHIEF MEDICAL OFFICER
CHIEF MEDICAL OFFICER
Filed Aug 19, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$227,649.63Shares × reported price
Shares traded
3,900Common Stock
Price per share
$58.37Reported price. Read footnotes for ranges.
% of reported position traded
13%This security and ownership context
Holdings after
26,100Direct
Trade date
Aug 17, 2026Sell
Filed
Aug 19, 2026, 4:16 PM ET2-day reporting delay
Accession
0001701247-26-000012Code S · Transaction 11061
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 30,000 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 17, 2026Sell1,100$59.35−$65,281.15Trade 11062
Aug 17, 2026Option exercise5,000$2.48$12,400Trade 11060
Aug 17, 2026Option exercise5,000$0.00$0Trade 11063
4 transaction rows in this filing. Joint filers share the same rows.

ELVN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ELVN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −10%1w ago +0.1%1d ago −1%
Returns since7d +2.5%30d −15%90d180d1y

Footnotes in full

F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. F2: Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. F3: This transaction was executed in multiple trades at prices ranging from $57.895 to $58.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F4: This transaction was executed in multiple trades at prices ranging from $58.985 to $59.535. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F5: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU. F6: All of the shares subject to this option are fully vested and exercisable as of the date hereof.